One hundred and thirty-one women with chronic hypertension were studied serially during pregnancy to determine the sequence of events in the development of superimposed pre-eclampsia and to discover the time of onset. Twenty-seven women developed a sustained rise in plasma urate concentrations, which began at about 28 weeks' gestation and which is characteristic of pre-eclampsia. The mean platelet count was already significantly reduced and&continued to fall until delivery, which was on average at 36 weeks' gestation. A comparable but smaller decrease in platelet count was seen in 55 women who had borderline but consistent increases in plasma urate concentrations. In 49 women whose plasma urate concentrations remained steady the platelet count did not change significantly before delivery.
Introduction
Changes in the coagulation system in established pre-eclampsia are well documented1 2 and distinguish pre-eclampsia from chronic hypertension coinciding with pregnancy. 3 The time of onset of the coagulation disturbance is a matter of controversy, but longitudinal studies have suggested that it is a late secondary feature of pre-eclampsia. 4 The most definitive examination of the problem6 was inconclusive because no severe cases of preeclampsia developed in the 60 primigravidae selected for serial investigation.
In a preliminary study of the evolution of severe preeclampsia we found that a fall in the circulating platelet count occurred earlier in pre-eclampsia than had been suspected. 7 We therefore expanded this investigation and studied chronically hypertensive women, who have a high risk of developing preeclampsia8 and whose coagulation indices3 do not differ from those of normal women. As an index of the development of superimposed pre-eclampsia9 we used serial plasma urate concentrations. This is a new technique, which was used for the first time in this study. A definite increase in plasma urate concentration was recorded when it rose at least 120 tmol/l (2 mg/100 ml) above the baseline measurement on two successive occasions, usually one or two weeks apart. The time that the increase began was defined as the time of the first follow-up visit at which the plasma urate concentration was consistently 60 tsmol/l (1 mg/100 ml) above the baseline reading. A borderline increase in plasma urate concentration was defined as 30 stmol/l (0-5 mg/100 ml) above the baseline measured on three successive occasions, the time at which it began being taken as the time of the first measurement. Patients with no consistent change in plasma urate concentration served as controls. Changes in platelet counts were determined in relation to the point at which the plasma urate concentration first began to increase. The control patients were matched for gestational maturity with the patients whose plasma urate concentrations showed changes characteristic of pre-eclampsia. Results from both groups were analysed and compared. All analyses were carried out "blind" by computer, so that the time of onset of a rise in plasma urate concentration was calculated without knowledge of the platelet counts.
Proteinuria was diagnosed when two midstream specimens of urine contained 0-2 g or more of protein/l without evidence of infection or when one midstream specimen contained 1 0 g or more/l without evidence of infection.
Results
Of the 131 women studied, 27 developed an increase in plasma urate concentration diagnostic of the renal changes of severe pre-eclampsia at a mean time of 206 days (table I) . Fifty-five women had borderline increases characteristic of mild pre-eclampsia, which were first detectable at a mean time of 247 days. The remaining 49 "normal" women had no consistent change in plasma urate concentrations.
The characteristics of the three groups were similar (table II) . The normal women included slightly more multiparae than did the other two groups, but the difference was not significant. The one perinatal death in this group was caused by rhesus isoimmunisation. In the group with definitely increased plasma urate concentrations the mean maternal height was significantly less than in the other groups. The one perinatal death was caused by severe pre-eclampsia. Compared with the control group there was both a significant excess of small babies and a deficit of large babies, and maturity at delivery was significantly reduced, reflecting the severity of the pre-eclampsia (P < 0 01; Student's t test). In the more severely affected group this difference had already been established by the time the consistent rise in plasma urate concentration began-that is, at 29 weeks, or about seven weeks before delivery (fig 1) . At the two earlier examinations the mean platelet counts had already begun to fall, but the difference from that of the normal group was not significant. The group with borderline increases in plasma urate concentrations had similar but less pronounced changes in the mean platelet count, with a small but consistent reduction already developed by 32 weeks, about six weeks before delivery (fig 2) . More patients in the groups with increased plasma urate concentrations were receiving antihypertensive treatment, so that strict comparisons between mean blood pressures could not be made. Nevertheless, the mean maximum blood pressure in the group with definitely increased plasma urate concentrations was significantly above the means of the two other groups. Furthermore, proteinuria was seen in 10 (37 %) of 
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Discussion
The question whether the platelet count falls as normal pregnancy progresses is controversial.'" Fenton et al reported no change in a serial study of one cohort of women,'2 which agrees with our observations in patients who did not develop the renal changes of pre-eclampsia. Our study of platelet counts in pregnancy was the first to use plasma urate measurements to determine the onset and progression of pre-eclampsia. This permitted objective identification and exclusion of patients with borderline as well as established features of pre-eclampsia. The results suggest that a falling platelet count in pregnancy is primarily a feature of pre-eclampsia. Other studies reporting a falling platelet count in the third trimester of normal pregnancy may have been biased by the inclusion of undiagnosed cases of pre-eclampsia. Our observations also show that this reduction in platelet count occurs early in the development of preeclampsia, being detectable about seven weeks before delivery. This confirms our earlier, smaller study.7
The lower platelet counts in severe pre-eclampsia are associated with abnormal activation of the coagulation system and are believed to reflect increased platelet consumption. Probably, platelet consumption is increased before lower counts are detected, which raises the question of what part platelet-count and coagulation changes play in the aetiology of pre-eclampsia. In particular, it is not clear whether these peripheral changes are a cause or a consequence of the occlusive vascular lesions in the uteroplacental arteries associated with fetal growth retardation."3
Because of the variation in counts between patients no diagnostic importance can be attached to a single low reading; thus platelet counts would not be a good screening test for pre-eclampsia. They are simpler to obtain than other measurements of disturbed coagulation, however, and repeated readings in the same patient can be useful in showing a consistent trend towards lower counts, which may herald the onset of preeclampsia. Thus the platelet count can be helpful in monitoring high-risk pregnancies.
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